How to buy Johnson-and-Johnson (JNJ) stocks

Johnson-and-Johnson is a drug manufacturers - general business based in the US. Johnson-and-Johnson shares (JNJ) are listed on the NYSE and all prices are listed in US Dollars.

Its last market close was $149.31 – a decrease of 3.68% over the previous week. Johnson-and-Johnson employs 131,900 staff and has a trailing 12-month revenue of around $87.7 billion.

Our top picks for where to buy Johnson-and-Johnson stock

Buy Johnson-and-Johnson stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

Related: Compare the best stock trading platforms in Canada

Johnson-and-Johnson stock price (NYSE: JNJ)

Use our graph to track the performance of JNJ stocks over time.

Johnson-and-Johnson stocks at a glance

• Key figures

Information last updated 2024-12-04.

Latest market close	$149.31
52-week range	$139.79 - $167.51
50-day moving average more info button	$158.91
200-day moving average more info button	$155.78
Wall St. target price	$174.89
PE ratio more info button	25.2044
Dividend yield more info button	$4.86 (3.26%)
Earnings per share (TTM) more info button	$5.97

Is it a good time to buy Johnson-and-Johnson stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Dive deeper: Our picks for the best stocks to buy right now in Canada

Johnson-and-Johnson price performance over time

Historical closes compared with the close of $149.31 from 2024-12-06

1 week (2024-11-29)	-3.68%
1 month (2024-11-08)	-3.96%
3 months (2024-09-06)	-9.17%
6 months (2024-06-07)	1.52%

1 year (2023-12-08)	-3.31%
2 years (2022-12-08)	-10.43%
3 years (2021-12-08)	150.6473
5 years (2019-12-06)	22.19%

Is Johnson-and-Johnson stock undervalued or overvalued?

Valuing Johnson-and-Johnson stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Johnson-and-Johnson's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Johnson-and-Johnson's P/E ratio

Johnson-and-Johnson's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 25x. In other words, Johnson-and-Johnson shares trade at around 25x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the stock or simply that they're under-valued.

Johnson-and-Johnson's PEG ratio

Johnson-and-Johnson's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.9074. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Johnson-and-Johnson's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

Johnson-and-Johnson's EBITDA

Johnson-and-Johnson's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $30.1 billion.

The EBITDA is a measure of a Johnson-and-Johnson's overall financial performance and is widely used to measure a its profitability.

Johnson-and-Johnson financials

Revenue TTM	$87.7 billion
Operating margin TTM	24.52%
Gross profit TTM	$64 billion
Return on assets TTM	8.4%
Return on equity TTM	20.89%
Profit margin	16.74%
Book value	$29.14
Market Capitalization more info button	$362.3 billion

TTM: trailing 12 months

Johnson-and-Johnson stock dividends

Dividend payout ratio: 47.95% of net profits

Recently Johnson-and-Johnson has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Johnson-and-Johnson shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Johnson-and-Johnson's case, that would currently equate to about $4.86 per share.

While Johnson-and-Johnson's payout ratio might seem fairly standard, it's worth remembering that Johnson-and-Johnson may be investing much of the rest of its net profits in future growth.

Johnson-and-Johnson's most recent dividend payout was on 9 December 2024. The latest dividend was paid out to all shareholders who bought their stocks by 25 November 2024 (the "ex-dividend date").

Have Johnson-and-Johnson's stocks ever split?

Johnson-and-Johnson's stocks were split on a 2:1 basis on 12 June 2001 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Johnson-and-Johnson stocks – just the quantity. However, indirectly, the new 50% lower stock price could have impacted the market appetite for Johnson-and-Johnson stocks, which in turn could have impacted Johnson-and-Johnson's stock price.

Johnson-and-Johnson stock price volatility

Over the last 12 months, Johnson-and-Johnson's stocks have ranged in value from as little as $139.7911 up to $167.5059. A popular way to gauge a stock's volatility is its "beta."

Beta is a measure of a stocks volatility in relation to the market. The market (NYSE average) beta is 1, while Johnson-and-Johnson's is 0.518. This would suggest that Johnson-and-Johnson's stocks are less volatile than average (for this exchange).

Johnson-and-Johnson overview

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

Related: New to stock trading? Compare brokers and get tips for investing.

Frequently asked questions

What percentage of Johnson-and-Johnson is owned by insiders or institutions?
Currently 0.091% of Johnson-and-Johnson stocks are held by insiders and 73.11% by institutions. How many people work for Johnson-and-Johnson?
Latest data suggests 131,900 work at Johnson-and-Johnson. When does the fiscal year end for Johnson-and-Johnson?
Johnson-and-Johnson's fiscal year ends in December. Where is Johnson-and-Johnson based?
Johnson-and-Johnson's address is: One Johnson & Johnson Plaza, New Brunswick, NJ, United States, 08933 What is Johnson-and-Johnson's ISIN number?
Johnson-and-Johnson's international securities identification number is: US4781601046 What is Johnson-and-Johnson's CUSIP number?
Johnson-and-Johnson's Committee on Uniform Securities Identification Procedures number is: 478160104

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.